Angelo Scopelianos notified Axogen, Inc. of his intention to resign as the Company's Chief Research and Development Officer no later than March 31, 2024. Mr. Scopelianos will provide transition services as a consultant for a period commencing on the Separation Date and ending on December 31, 2024. The Consulting Period may be extended further upon mutual agreement of the Company and Mr. Scopelianos and may be terminated by the Company for cause.

Mr. Scopelianos' product development responsibilities will be assumed by Ms. Stacy Arnold, Vice President of Product Development and Clinical Research, who is not an executive officer but is a member of the executive team and reports directly to the Company's CEO, Karen Zaderej.